[CAS NO. 14663-23-1] Dantrolene sodium
PRODUCTS SPECIFICATIONS [14663-23-1]
DESCRIPTION [14663-23-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 336.23 |
| Molecular Formula | C14H9N4NaO5 |
| SMILES | O=C([N-]1)N(/N=C/C2=CC=C(C3=CC=C([N+]([O-])=O)C=C3)O2)CC1=O.[Na+] |
7 Publications Citing Use of MCE
Summary
Dantrolene sodium is a inhibitor of calcium channel proteins, inhibiting the release of Ca2+ from the sarcoplasm. Dantrolene sodium is a skeletal muscle relaxant which acts by blocking muscle contraction beyond the neuromuscular junction.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02513095 | Eagle Pharmaceuticals, Inc.|Quintiles, Inc. |
Heat Stroke
|
September 2015 | Phase 2 |
| NCT01024972 | University of Massachusetts, Worcester|American Heart Association |
Subarachnoid Hemorrhage|Cerebral Vasospasm
|
October 2009 | Phase 1|Phase 2 |
| NCT03762109 | Beth Israel Deaconess Medical Center |
Lumbar Spine Injury
|
July 29, 2019 | Phase 2 |
| NCT00964548 | University of Massachusetts, Worcester|Massachusetts General Hospital |
Cerebral Vasospasm After Subarachnoid Hemorrhage
|
July 2007 | Phase 1|Phase 2 |
| NCT02829268 | Washington University School of Medicine|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Wolfram Syndrome|Diabetes Mellitus|Optic Nerve Atrophy|Ataxia
|
January 2017 | Phase 1|Phase 2 |
| NCT01950520 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) |
Healthy Volunteers
|
February 7, 2014 | Phase 2 |
| NCT00796900 | Medical University of Vienna |
Hyperthermia
|
May 2008 | Phase 2|Phase 3 |
| NCT03109288 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) |
Multiple Sclerosis
|
August 11, 2017 | Phase 1|Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 4.17 mg/mL ( 12.40 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.9742 mL | 14.8708 mL | 29.7415 mL |
| 5 mM | 0.5948 mL | 2.9742 mL | 5.9483 mL |
| 10 mM | 0.2974 mL | 1.4871 mL | 2.9742 mL |